Search - tctmd.com

Displaying 961 - 980 of 2527

Sort: Relevancy | Date

COOL-AMI Fails to Show Benefit of Rapid Cooling in STEMI

News Conference News EuroPCR 2021

COOL-AMI Fails to Show Benefit of Rapid Cooling in STEMI

Yael L. Maxwell

May 20, 2021

Complete 2-Year Data From Evolut Low-Risk Trial ‘Reassuring’ for TAVI

News Conference News EuroPCR 2021

Complete 2-Year Data From Evolut Low-Risk Trial ‘Reassuring’ for TAVI

Yael L. Maxwell

May 19, 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

CLASP 2-Year Data Promising for Pascal Transcatheter Mitral RepaiR

News Conference News EuroPCR 2021

CLASP 2-Year Data Promising for Pascal Transcatheter Mitral Repair

May 19, 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

News Conference News EuroPCR 2021

Elective Revascularization, Better Long-term Survival: Meta-analysis

Michael O'Riordan

May 18, 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

May 18, 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

Lancet Commission on CVD in Women Aims to Slash Global Burden

News Conference News ACC 2021

Lancet Commission on CVD in Women Aims to Slash Global Burden

May 17, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

COVID-19 Doubled Burnout Rates in Cardiology

News Conference News ACC 2021

COVID-19 Doubled Burnout Rates in Cardiology

Yael L. Maxwell

May 17, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

May 16, 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

News Conference News ACC 2021

REHAB-HF: Tailored Cardiac Rehab Promotes Physical Function After Hospital Stay

May 16, 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

News Conference News ACC 2021

Use of a Rapid, High-Sensitivity Troponin Protocol Doesn’t Boost 1-Year Outcomes

May 16, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

May 16, 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

May 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.